Academic Journal
Cohort Profile:The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE)
| العنوان: | Cohort Profile:The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE) |
|---|---|
| المؤلفون: | Stærke, Nina Breinholt, Reekie, Joanne, Johansen, Isik S, Nielsen, Henrik, Benfield, Thomas, Wiese, Lothar, Søgaard, Ole S, Tolstrup, Martin, Iversen, Kasper Karmark, Tarp, Britta, Larsen, Fredrikke Dam, Larsen, Lykke, Lindvig, Susan Olaf, Holden, Inge Kristine, Iversen, Mette Brouw, Knudsen, Lene Surland, Fogh, Kamille, Jakobsen, Marie Louise, Traytel, Anna Katrin, Ostergaard, Lars, Lundgren, Jens |
| المصدر: | Stærke , N B , Reekie , J , Johansen , I S , Nielsen , H , Benfield , T , Wiese , L , Søgaard , O S , Tolstrup , M , Iversen , K K , Tarp , B , Larsen , F D , Larsen , L , Lindvig , S O , Holden , I K , Iversen , M B , Knudsen , L S , Fogh , K , Jakobsen , M L , Traytel , A K , Ostergaard , L , Lundgren , J & ENFORCE Study Group 2022 .... |
| سنة النشر: | 2022 |
| المجموعة: | Aarhus University: Research |
| مصطلحات موضوعية: | COVID-19, IMMUNOLOGY, Infection control |
| الوصف: | PURPOSE: The ENFORCE cohort is a national Danish prospective cohort of adults who received a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine as part of the Danish National SARS-CoV-2 vaccination programme. It was designed to investigate the long-term effectiveness, safety and durability of SARS-CoV-2 vaccines used in Denmark. PARTICIPANTS: A total of 6943 adults scheduled to receive a SARS-CoV-2 vaccine in the Danish COVID-19 vaccination programme were enrolled in the study prior to their first vaccination. Participants will be followed for a total of 2 years with five predetermined follow-up visits and additional visits in relation to any booster vaccination. Serology measurements are performed after each study visit. T-cell immunity is evaluated at each study visit for a subgroup of 699 participants. Safety information is collected from participants at visits following each vaccination. Data on hospital admissions, diagnoses, deaths and SARS-CoV-2 PCR results are collected from national registries throughout the study period. The median age of participants was 64 years (IQR 53-75), 56.6% were women and 23% were individuals with an increased risk of a serious course of COVID-19. A total of 340 (4.9%) participants tested positive for SARS-CoV-2 spike IgG at baseline. FINDINGS TO DATE: Results have been published on risk factors for humoral hyporesponsiveness and non-durable response to SARS-CoV-2 vaccination, the risk of breakthrough infections at different levels of SARS-CoV-2 spike IgG by viral variant and on the antibody neutralising capacity against different SARS-CoV-2 variants following primary and booster vaccinations. FUTURE PLANS: The ENFORCE cohort will continuously generate studies investigating immunological response, effectiveness, safety and durability of the SARS-CoV-2 vaccines. TRIAL REGISTRATION NUMBER: NCT04760132. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | https://pure.au.dk/portal/en/publications/98d0365d-e313-4dfc-9995-672add5c3e8d |
| DOI: | 10.1136/bmjopen-2022-069065 |
| الاتاحة: | https://pure.au.dk/portal/en/publications/98d0365d-e313-4dfc-9995-672add5c3e8d https://doi.org/10.1136/bmjopen-2022-069065 http://www.scopus.com/inward/record.url?scp=85145425009&partnerID=8YFLogxK |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.48040245 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1136/bmjopen-2022-069065 |
|---|